MENU

Increasing Body Mass Index Linked with Worse Localized Prostate Cancer Outcomes

May 29, 2015

PHILADELPHIA (May 29, 2015) — An increasing body mass index (BMI) was associated with a higher rate of prostate cancer relapse, prostate cancer death, and death from any cause among men treated with dose-escalated intensity-modulated radiotherapy for localized prostate cancer, according to the results of a retrospective study by Fox Chase Cancer Center researchers.

"Based on this study, men with higher BMI have worse prostate cancer-specific outcomes, as well as an increased risk for dying from any cause compared to men with lower BMI when treated similarly," said Lora S. Wang, MD, of the department of radiation oncology at Fox Chase. "Obesity and its effects on cancer treatment and outcomes should undergo further study to better elucidate the relationship."

Previous research has shown that obese men have an increased risk for death from prostate cancer compared with men with a normal BMI. However, the exact effects of BMI in men treated with external beam radiation therapy are less clear, and few studies have evaluated the effect of obesity in the era of dose-escalated intensity-modulated radiotherapy—techniques that include a more focused area of treatment, higher radiation doses, and the use of daily imaging to help pinpoint the radiation.

In the study, which was published in Cancer, Dr. Wang and colleagues identified 1,442 patients with localized prostate cancer treated at Fox Chase with definitive intensity-modulated radiation therapy and image-guided radiation therapy between 2001 and 2010. The researchers then analyzed whether BMI had any effect on outcomes.

About 20 percent of the included patients had a BMI of less than 25 kg/m2, 48 percent had a BMI of 25 to 29.9 kg/m2, 23 percent had a BMI of 30 to 34.9 kg/m2, 6 percent had a BMI of 35 to 39.9 kg/m2, and 4 percent had a BMI of 40 kg/m2 or greater. The median age of patients was 68 years and the median radiation dose was 78 gray.

Increasing BMI was found to be associated with a small but increased rate of prostate cancer relapse (3 percent) in men treated with external beam radiation therapy. In addition, increasing BMI was also linked with small but significant increases in distant metastases (7 percent), prostate cancer-specific mortality (15 percent), and overall mortality (5 percent).

According to Dr. Wang, the exact mechanism of this association is unclear, although studies have shown that obesity increases certain cellular factors and hormones, which in turn may lead to more aggressive cancer and rapid progression. "All patients should be counseled on diet and exercise as well as any potential lifestyle changes to obtain or maintain a healthy weight," Dr. Wang said.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase